UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

THU0169 Persistence of Tofacitinib in The Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up To 7 Years

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.245-245

2016

Volltextzugriff (PDF)

THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.258-258

2016

Volltextzugriff (PDF)

THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.252-252

2016

Volltextzugriff (PDF)

P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S361-S362

2021

Volltextzugriff (PDF)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Arthritis research & therapy, 2019-04, Vol.21 (1), p.89-18, Article 89

2019

Volltextzugriff (PDF)

Effect of Abrocitinib and Dupilumab on Eosinophil Levels in Patients With Moderate-to-Severe Atopic Dermatitis and With or Without Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB153-AB153

2023

Volltextzugriff (PDF)

S760 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S351-S351

2021

Volltextzugriff (PDF)

S761 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S351-S351

2021

Volltextzugriff (PDF)

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2200866-2200866

2023

Volltextzugriff (PDF)

43916 Efficacy and Safety of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the Presence or Absence of Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB156-AB156

2023

Volltextzugriff (PDF)

Abrocitinib may improve itch and quality of life in patients with itch‐dominant atopic dermatitis

Skin health and disease, 2024-08, Vol.4 (4), p.e382-n/a

2024

Volltextzugriff (PDF)

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

The Lancet (British edition), 2021-11, Vol.398 (10315), p.1984-1996

2021

Volltextzugriff (PDF)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2019-05, Vol.71 (5), p.685-695

2019

Volltextzugriff (PDF)

359 Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Volltextzugriff (PDF)

Tofacitinib for juvenile idiopathic arthritis – Authors' reply

The Lancet (British edition), 2022-05, Vol.399 (10338), p.1866-1866

2022

Volltextzugriff (PDF)

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open

Alimentary pharmacology & therapeutics, 2022-06, Vol.55 (12), p.1534-1544

2022

Volltextzugriff (PDF)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Rheumatology and therapy., 2023-10, Vol.10 (5), p.1255-1276

2023

Volltextzugriff (PDF)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

ACR open rheumatology, 2019-04, Vol.1 (2), p.73-82

2019

Volltextzugriff (PDF)

The Effectiveness of Zoster Vaccine in Patients Subsequently Treated With Tofacitinib: 748

The American journal of gastroenterology, 2017-10, Vol.112, p.S416-S417

2017

Volltextzugriff (PDF)

Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis

Skin (Milwood, N.Y.), 2023-03, Vol.7 (2), p.s154

2023

Volltextzugriff (PDF)

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies

CNS spectrums, 2009-09, Vol.14 (9), p.478

2009

Volltextzugriff (PDF)

Economic evaluations of Alzheimer's disease medications: Review and an application

Lazariciu, Irina

2004

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(21)
Dissertationen
(1)

Sprache

Englisch
(22)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(6)
Life Sciences & Biomedicine
(6)
Science & Technology
(6)
Drug Dosages
(5)
Rheumatoid Arthritis
(5)
Rheumatology
(5)
Arthritis
(4)
Original
(4)
Piperidines - Therapeutic Use
(4)
Pyrimidines - Therapeutic Use
(4)
Treatment Outcome
(4)
Adolescent
(3)
Adult
(3)
Patients
(3)
Pyrroles - Therapeutic Use
(3)
Rheumatoid Factor
(3)
Administration, Oral
(2)
Aged
(2)
Arthritis, Rheumatoid - Drug Therapy
(2)
Children
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

THU0169 Persistence of Tofacitinib in The Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up To 7 Years

THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Effect of Abrocitinib and Dupilumab on Eosinophil Levels in Patients With Moderate-to-Severe Atopic Dermatitis and With or Without Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

S760 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response

S761 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

43916 Efficacy and Safety of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the Presence or Absence of Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

Abrocitinib may improve itch and quality of life in patients with itch‐dominant atopic dermatitis

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

359 Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab

Tofacitinib for juvenile idiopathic arthritis – Authors' reply

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

The Effectiveness of Zoster Vaccine in Patients Subsequently Treated With Tofacitinib: 748

Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies

Economic evaluations of Alzheimer's disease medications: Review and an application

Suchergebnisse filtern